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Abstract
Background: No therapies have been proven to persistently improve the outcome of HTLV-I-
associated myelopathy. Clinical benefit has been reported with zidovudine and with lamivudine in
observational studies. We therefore conducted a randomised, double blind, placebo controlled
study of six months combination therapy with these nucleoside analogues in sixteen patients.
Results: Primary outcomes were change in HTLV-I proviral load in PBMCs and clinical measures.
Secondary endpoints were changes in T-cell subsets and markers of activation and proliferation.
Six patients discontinued zidovudine. No significant changes in pain, bladder function, disability
score, gait, proviral load or markers of T-cell activation or proliferation were seen between the
two arms. Active therapy was associated with an unexplained decrease in CD8 and non-T
lymphocyte counts.
Conclusion: Failure to detect clinical improvement may have been due irreversible nerve damage
in these patients with a long clinical history and future studies should target patients presenting
earlier. The lack of virological effect but may reflect a lack of activity of these nucleoside analogues
against HTLV-I RT in vivo, inadequate intracellular concentrations of the active moiety or the
contribution of new cell infection to maintaining proviral load at this stage of infection may be
relatively small masking the effects of RT inhibition.
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Background
The first identified human retrovirus, Human T-cell Lym-
photropic Virus Type I (HTLV-I) [1], was initially associ-
ated with Adult T-cell Leukaemia/Lymphoma[2] before
becoming causally associated with a chronic inflamma-
tory myelopathy (HTLV-I associated myelopathy,
HAM)[3,4] in a minority of carriers. In Japan it has been
estimated that the lifetime risk of HAM among the one
million infected persons is 0.25%[5] whilst in England,
the estimated 22,000 carriers, of mainly African descent,
have a 3% lifetime risk[6].
The onset of HAM is usually sub-acute and the initial pre-
senting symptoms may relate to the urinary bladder, bow-
els or sexual function as well as gait disturbance or back
pain. Diagnosis is often delayed until the more character-
istic constellation of combined symptoms appears some
months or years later. The most rapid progression is usu-
ally seen within the first two years with the neurological
deficit varying from mild gait impairment to paraplegia.
Thereafter some patients remain relatively stable whilst
slow deterioration compounded by physiological aging is
observed in others. In our experience approximately half
of all patients become wheel-chair dependant and
although many patients with HAM have a normal life
span, premature deaths directly related to HAM occur.
The pathogenesis of HAM is not fully understood but sev-
eral observations point to potential therapeutic
approaches. An association between proviral load and dis-
ease has been repeatedly found with proviral load, as
measured by HTLV-I DNA copies in peripheral blood
mononuclear cells (PBMCs), about ten fold higher in
patients with HAM than in asymptomatic carriers[7,8]
and the risk of disease increases exponentially if the pro-
viral load is greater than one HTLV-I DNA copy per 100
PBMCs[9]. Thus measures to reduce viral burden could
potentially reduce the risk, or modify the course of the dis-
ease. Neuropathological examination reveals a perivascu-
lar lymphocytic infiltration in the spinal cord that is
composed predominantly of CD4 positive T-lymphocytes
(CD4 cells) in early disease and CD8 positive T- lym-
phocytes (CD8 cells) in later disease followed by a less cel-
lular, atrophic phase[10,11]. The same cell types can be
found in the cerebrospinal fluid of patients with
HAM[12]. Like other cytotoxic T-lymphocytes (CTL)
HTLV-I specific CTL have been shown to release poten-
tially neurotoxic cytokines such as interferon-γ (IFN-γ)
and tumour necrosis factor-α (TNF-α)[13]. In the periph-
ery HTLV-I-specific CD4 T cells differ much more in fre-
quency between patients with HAM and asymptomatic
carriers than do anti-HTLV CTL and these also secrete IFN-
γ and TNF-α [14]. Thus therapies, which might modulate
the immune response such as corticosteroids and interfer-
ons, have also been considered.
The literature on the specific management of HAM con-
sists mostly of small, uncontrolled studies and cohort
data. Conflicting results have been obtained in studies of
corticosteroids therapy[15]. Interferon-α has been shown
to be of short-term benefit in some patients in a ran-
domised study comparing three different dose regimens
with evidence of a dose dependant response[16]. Some
nucleoside analogues have been shown to inhibit HTLV-I
reverse transcriptase. The thymidine analogue, zidovu-
dine, which inhibits HTLV-I RT in vitro[17,18] and in a
rabbit infection model[19], was reported to show no clin-
ical benefit in a study of six patients with chronic dis-
ease[20] but associated with improved mobility is some
patients in a second study[21]. The cytosine analogue,
lamivudine, was reported to reduce HTLV-I proviral load
in five patients with clinical improvement in one patient
with early disease[22]. All three studies were small, open
and uncontrolled. In the management of both HIV and
hepatitis B virus treatment with nucleoside analogues fails
because of the emergence of viral strains with reduced sen-
sitivity to these compounds especially when the drugs are
used singly.
We report here the results of a randomised, double blind,
placebo controlled study of the combination of zidovu-
dine and lamivudine to determine their safety and efficacy
with medium term (six to twelve months) usage.
Results
Sixteen patients were recruited to the study, twelve in Lon-
don and four in Kagoshima. Eight were randomly
assigned to each study arm. Baseline demographics, clini-
cal and laboratory characteristics of the participants are
shown in Table 1. Treatment was initiated on the day of
randomisation in seven participants, within two weeks for
seven participants and after two weeks for two partici-
pants. All participants were followed up to week 48.
Adherence
Mean red cell volume rose during the first 24 weeks of the
study in the active arm. At week 24, 100% of patients in
the active arm and 0% in the placebo arm had a change in
MCV from baseline greater than 3 within-person SDs.
During the second 24 weeks of the study a similar rise in
MCV was seen in the placebo arm at week 48, 75% of
patients in each arm had a change in MCV from baseline
greater than 3 within-person SDs. There was good consist-
ency between lamivudine and zidovudine returned tablet
counts but the average number of tablets returned in the
previous month rose from 9.5% at the end of the 3rd
month to 25.5% at the end of the 6th month. There was lit-
tle detectable difference in returned tablet counts between
the two arms or between the first, randomised and sec-
ond, open phases of the study.Retrovirology 2006, 3:63 http://www.retrovirology.com/content/3/1/63
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Table 1: Baseline characteristics
Placebo (n = 8) Active (n = 8) Total (n = 16)
Demographics
Country [n(%)]
England 6 (75) 6 (75) 12 (75)
Japan 2 (25) 2 (25) 4 (25)
Gender [n(%)]
Male 4 (50) 1 (13) 5 (31)
Ethnic origin [n(%)]
Afro-Caribbean 5 (63) 5 (63) 10 (63)
Indian 1 (13) 0 (0) 1 (6)
Japanese 2 (25) 2 (25) 4 (25)
Persian 0 (0) 1 (13) 1 (6)
Age at randomisation
mean years (SD) 61.0 (10.8) 53.9 (15.5) 57.4 (13.4)
Likely mode of infectiona [n(%)]
Mother to child 3 (30) 5 (33) 8 (32)
Blood transfusion 1 (10) 2 (13) 3 (12)
Sexual intercourse 2 (20) 6 (40) 8 (32)
Unknown 4 (40) 2 (13) 6 (24)
Clinical Characteristics
Pain score: scale 0–10
median (range) 2.2 (0–5) 2.6 (0–8) 2.6 (0–8)
Osame's score [n(%)]
0 – 4 (Unaided walk) 3 (38) 3 (38) 6 (38)
5 – 8 (Needs aid to walk) 4 (50) 3 (38) 7 (44)
9 – 13 (Unable to walk) 1 (13) 2 (25) 3 (19)
Time to walk 13 m in seconds [mean (SD)]
0 – 4 (Unaided walk) 19 (13) 13 (2) 16 (9)
5 – 8 (Needs aid to walk) 82b (65) 112 (112) 95b (81)
Bladder functionc [median (range)]
Daytime frequency 5 (4–8) 4.5 (2–8) 5 (2–8)
Nocturia 4 (3.5–4) 2 (0.5–4) 4 (0.5–4)
Duration of symptoms in years
median (range) 10.5 (5 – 19) 9 (1–18) 9 (1–19)
Laboratory Measurements*
HTLV-I proviral loadd (log10 copies/105 PBMCs)
mean (SD) 3.57 (0.44) 3.76 (0.39) 3.67 (0.41)
Total lymphocytese (106/L) 1600 (1250–2600) 1800 (1250–3000) 1775 (1250–3000)
CD3 lymphocytese (106/L) 1165(488–2018) 1240(430–2144) 1190(430–2144)
CD3e % 71 (35–81) 69 (34–90) 71 (34–90)
CD4e lymphocytes (106/L) 802(340–1670) 801(334–1375) 801(334–1670)
CD4e % 39 (25–67) 44 (27–59) 44 (25–67)
CD8e lymphocytes (106/L) 375 (149–941) 185 (96–840) 362 (96–941)
CD8e % 27 (11–36) 10 (6–46) 21 (6–46)
CD25d % 3 (2–26) 7 (2–33) 3 (2–33)
CD69d % 8 (4–10) 7 (4–14) 7 (4–14)
CD71d % 9 (3–12) 7 (3–18) 8 (3–18)
HLA-DR% 20 (13–40) 9 (5–16) 15 (5–40)
*median (range) unless otherwise specified
a Total exceeds 16 because more than one possible mode of infection was documented in some patients
b One patient could only walk half distance. For the analysis their timed walk was doubled
c One patient in each group is excluded from the analysis because they had an indwelling urinary catheter.
A further 5 patients (3 in placebo group, 2 in active group) have missing nightly frequencies. Values given as average daily/nightly urinary frequency 
between screening and week 0
d Baseline data only available on n = 6 in placebo group and n = 7 in active group
e Baseline data only available on n = 7 in placebo group and n = 7 in active groupRetrovirology 2006, 3:63 http://www.retrovirology.com/content/3/1/63
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Safety
During the first 24 weeks of the study no participants in
the placebo arm discontinued therapy. In the active arm
one participant, whose disease had progressed from first
symptom to bed-bound in the 9 months prior to study
entry, was un-blinded at week 8 because of continuing
deterioration. Interferon-α was added to the active com-
pounds until week 20 when zidovudine was discontinued
following the development of autoimmune haemolytic
anaemia. During the second 24-week period of open ther-
apy 5 participants previously on placebo discontinued
zidovudine, one within 4 weeks, with gastrointestinal
symptoms, the remainder after 16 – 20 weeks of therapy.
Two had anaemia, one necessitating blood transfusion,
one complained of drowsiness and paraesthesia and one
of lethargy. One participant from the active therapy arm
elected to discontinue therapy at week 40 when antibiot-
ics were prescribed out of study. No side affects attributa-
ble to lamivudine were reported. There were no significant
biochemical abnormalities.
Clinical efficacy
No significant changes in pain score, urinary frequency or
nocturia were seen between the active arm and the pla-
cebo arm during the study (Table 2) nor within the pla-
cebo arm when comparing the first 24 weeks on placebo
with the second 24 weeks on active therapy. Similarly
there was no consistent pattern of change in disability.
Timed walks remained relatively constant throughout the
study in most participants except for two in the placebo
arm whose timed walks improved between the two base-
line assessments and week 4 (Figure 1).
Laboratory markers of efficacy: The median (IQR) HTLV-I
proviral load at baseline was 4.2 (2.6–7.5) copies per 100
PBMCs (mean (SD) 3.7 (0.4) log10/100,000 PBMCs). No
significant change in proviral load was seen during the
first 24 weeks of the study in the active arm compared
with the placebo arm (mean difference (SE): 0.02 (0.17),
p = 0.92) (Table 3) nor within the placebo arm comparing
the first 24 weeks of placebo therapy with the second 24
weeks of active therapy (mean difference (SE): 0.12
(0.16), p = 0.50) (Table 4).
At baseline, the total lymphocyte, CD3, CD4 and CD8 cell
counts were normal. During the first 24 weeks the mean
total lymphocyte counts (AUCMB) increased by 148 ×
106/L in the placebo arm but decreased by 159 × 106/L in
the active arm, a mean difference of 307 × 106/L (SE =
158, p = 0.07) (Table 3). This trend was confirmed when
comparing the lymphocyte counts in participants on pla-
cebo compared with their counts when taking active ther-
apy, with the initial increase of 148 × 106/L followed by a
decrease of 71 × 106/L (mean difference (SE): 219 (73), p
= 0.02) (Table 4). Lymphocyte subset analysis of the first,
randomised therapy phase of the study, showed an
increase in CD4 in both arms and an increase in CD8 cells
in the placebo arm but a decrease in the active arm (Table
3). These changes were also seen when comparing the first
24 weeks of placebo treatment with the subsequent 24
weeks of active treatment in the placebo arm (Table 4).
However the major impact on the absolute lymphocyte
count appears mainly among non-T-lymphocytes with a
mean rise of 50 × 106/L non CD3 lymphocytes during the
first 24 weeks in the placebo arm compared with a mean
decrease of 127 × 106/L from baseline in the active arm, a
difference of 177 × 106/L (SE = 31, p < 0.001). A similar
trend was seen by comparing active with placebo therapy
in the placebo arm, although not statistically significant.
At baseline CD69 was expressed on average on 8%, CD71
on 8% and CD25 on 9% of lymphocytes. Compared with
placebo no significant changes were seen in these markers
of activation (CD69) and proliferation (CD71) nor in the
expression of the IL-2 receptor (CD25) (Tables 3 and 4)
during treatment with zidovudine plus lamivudine.
Table 2: Clinical outcome measures during randomised treatment phase presented as average [mean (SE)] changes from baseline 
during weeks 0 – 24 as measured by AUCMB
Placebo (n = 8) Active (n = 8) p
Osame's score +0.19 (0.19) +0.18 (0.34) 0.99
Pain score +0.43 (1.13) +0.41 (0.66) 0.99
Bladder function
Daytime frequencya -0.11 (0.38) -0.19 (0.62) 0.93
Nocturiab -0.18 (0.55) -0.81 (0.47) 0.41
a One patient in each group is excluded from the analysis because they had an indwelling urinary catheter
b One patient in each group is excluded from the analysis because they had an indwelling urinary catheter. The four Japanese patients had no night 
urinary frequency data (2 in each group) and baseline frequency was unknown for another patient in the placebo group. All are excluded from the 
analysis.Retrovirology 2006, 3:63 http://www.retrovirology.com/content/3/1/63
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Discussion
Since monotherapy with nucleoside analogues had been
reported to reduce HTLV-I viral load, the inhibition of
HTLV-I reverse transcriptase by two nucleoside analogues,
zidovudine and lamivudine was thought to be more likely
to cause a sustained decrease in HTLV-I viral burden than
either drug alone. A decrease in HTLV-I viral DNA and
thus a presumed decrease in viral antigen burden has been
associated with a reduction in HTLV-I specific CTL lym-
phocyte activity[22].
Since this activity is postulated to contribute to HAM
pathogenesis anti-HTLV therapy might in turn delay pro-
gression or cause clinical improvement.
Table 3: Laboratory outcome measures during randomised treatment phase presented as average [mean (SE)] changes from baseline 
during weeks 0 – 24 as measured by AUCMB
Placebo Active p
HTLV-I proviral loada (log10 copies/105 PBMCs) +0.03 (0.10) +0.05 (0.13) 0.92
Total Lymphocytesb (106/L) +148.2 (58.0) -159.3 (146.7) 0.07
CD3 Lymphocytesb (106/L) +98.4 (63.4) -23.2 (151.3) 0.47
CD3b % +0.2 (2.8) +4.3 (2.6) 0.14
CD4b Lymphocytes (106/L) +32.6 (33.1) +10.4 (98.7) 0.55
CD4b % -1.2 (0.9) +4.7 (1.8) 0.01
CD8b Lymphocytes (106/L) +65.8 (31.3) -38.1 (60.7) 0.15
CD8b % +1.4 (1.2) +1.4 (1.9) 0.99
CD25a % -0.8 (1.8) +0.3 (0.8) 0.58
CD69a % +0.4 (1.3) +1.2 (1.8) 0.73
CD71a% -0.3 (1.0) -0.2 (1.9) 0.97
HLA-DR% -4.85 (4.0) +3.59 (2.4) 0.42
a Data only available on n = 6 in placebo group and n = 7 in active group due to missing baseline data
b Data only available on n = 7 in placebo group and n = 7 in active group due to missing baseline data
Changes in timed 13 meter walk observed during the study period Figure 1
Changes in timed 13 meter walk observed during the study period.
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HAM is a rare disease in the UK with only 10 – 12 cases
diagnosed annually[23]. A similar number of cases are
seen in Kagoshima, Japan where the prevalence of infec-
tion is much higher. There is no licensed or clinically
proven effective therapy for HAM in the UK. However
short courses of interferon-α were made available by the
Japanese government for their patients with HAM coinci-
dent with the start of the study and this affected recruit-
ment in Japan.
Although the basic study design was double-blind and
placebo-controlled a second open-therapy phase was
incorporated, with all study participants offered open
therapy for a further six months, to maximise the likeli-
hood of detecting significant clinical and laboratory
changes. The study was not un-blinded until the last par-
ticipant had completed twelve months of therapy. In this
way the safety of zidovudine plus lamivudine could be
studied for a total of twelve months exposure whilst those
originally randomised to the placebo arm acted as their
own control for the second six months of active com-
pound in a non-randomised comparison.
The primary outcome measures of the study were the clin-
ical and virological effects of zidovudine in combination
with lamivudine. The failure to detect any clinical
improvement after up to 12 months of therapy may have
been due to the long history of HAM among the partici-
pants who had an average duration of symptoms of 10.1
years. After this prolonged time the neurological damage
may have been irreversible. However, the stability of the
HTLV-I viral DNA load, which was expected to fall during
the study, leaves the possibility that agents that effectively
reduced viral burden, might result in clinical improve-
ment even in longstanding disease.
The persistence of high viral load during therapy could be
due to a lack of activity of these nucleoside analogues
against HTLV-I RT, inadequate intracellular concentra-
tions of the active triphosphate metabolite, or it may be
that reverse transcription is not important in maintaining
HTLV-I proviral load at this stage of infection. Thus, whilst
a reduction in HTLV-I viral DNA during therapy with lam-
ivudine has been documented in vivo, there are now con-
flicting reports of its activity against HTLV-I RT in vitro
[24-26]. Conversely the in vitro inhibition of HTLV-I RT
by zidovudine has been confirmed[27]. Second, the intra-
cellular concentrations of the nucleoside analogues were
not measured in this study but HTLV-I Tax, which is
expressed within hours by the majority of HTLV-I infected
cells in unstimulated culture conditions, is known to
upregulate MDR-1[28]. Finally, the importance of HTLV-I
RT in maintaining HTLV-I proviral load remains uncer-
tain. Several paths of evidence point to continuing viral
protein expression[29] and HTLV-I has been shown to
spread directly from cell to cell, in ex vivo experiments,
through the formation of a virus induced synapse[30].
Whether cell-to-cell infection within the host is predomi-
nantly through virion production, binding and fusion or
directly through the viral synapse the reverse transcription
of HTLV-I RNA is required to establish new infection.
However HTLV-I infection is associated with proliferation
of the infected cells, a mechanism that contributes to the
total proviral load without the need of reverse transcrip-
tion.
Changes in the lymphocyte markers of activation and pro-
liferation might have been expected with a reduction in
HTLV-I proviral load. In the absence of such an effect the
observed, statistically significant, changes in total, CD4,
CD8 and non-CD3 lymphocytes are of interest albeit
unexplained.
Table 4: Laboratory outcome measures for the placebo group presented as average [mean (SE)] changes from baseline for the time 
on active therapy (weeks 24 – 48) compared with the time on placebo (weeks 0–24). Baseline values are the average of weeks – 2 and 0 
for 0 – 24 week analysis and the average of weeks 20 and 24 for 24 – 48 week analysis
Weeks 0–24 Weeks 24–48 P
HTLV-I proviral loada (log10 copies/105 PBMCs) +0.03 (0.10) -0.09 (0.08) 0.50
Total Lymphocytesb (106/L) +148.2 (58.0) -71.1 (63.1) 0.02
CD3 Lymphocytesb (106/L) +98.4 (63.4) +7.0 (39.2) 0.28
CD3b % +0.2 (2.8) +2.8 (2.0) 0.22
CD4b Lymphocytes (106/L) +32.6 (33.1) +30.4 (46.9) 0.97
CD4b % -1.2 (0.9) +3.6 (1.9) 0.08
CD8b Lymphocytes (106/L) +65.8 (31.3) -23.5 (13.7) 0.04
CD8b % +1.4 (1.2) -0.7 (1.1) 0.16
CD25a % -0.8 (1.8) -0.2 (1.3) 0.82
CD69a % +0.4 (1.3) -0.2 (3.0) 0.89
CD71a% -0.3 (1.0) +0.5 (1.3) 0.76
HLA-DR% -4.85 (4.0) +1.05 (2.3) 0.40
a Data only available on n = 6 due to missing baseline data
b Data only available on n = 7 due to missing baseline dataRetrovirology 2006, 3:63 http://www.retrovirology.com/content/3/1/63
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Conclusion
The data from this study do not provide evidence of
improvement in the clinical state of patients with HAM in
the medium term following treatment with the combina-
tion of zidovudine and lamivudine but the treatment was
well tolerated with no unexpected side effects. New, con-
trolled studies of both anti-viral and anti-inflammatory
agents are urgently required for patients with this chronic,
disabling disease. International co-operation will be nec-
essary to accelerate progress.
Methods
Study design
Patients were screened two weeks prior to baseline and eli-
gibility criteria checked. Recruitment was by the study
physicians at each site. The eligibility form was submitted
with a request for a trial number to the coordinating cen-
tre at the Medical Research Council. Trial numbers had
been randomly allocated, stratified by site, to active or
placebo and this code was held, sealed and secure, at the
MRC. Trial therapy was stored in site pharmacies and
labelled by trial name and trial number only. The trial
coordination staff at the MRC issuing the trial number,
the pharmacy, the clinician and the patient were all
blinded to the allocation of study arm. Trial numbers were
transmitted by facsimile to the study centres. Recruitment
commenced 8 November 1999. Eligible patients were ran-
domised to start 24 weeks treatment with zidovudine 300
mg plus lamivudine 150 mg twice daily (the active arm)
or matching zidovudine and lamivudine placebo tablets
(the placebo arm). This was followed by 24 weeks of open
therapy with the active compounds for all study partici-
pants. Last follow up was completed 30 July 2002. The
primary endpoints were virological – change in HTLV-I
viral DNA from baseline to 24 weeks and clinical –
changes in gait, disability, pain and bladder function. The
secondary endpoints were immunological – changes in
CD4, CD8, CD25, CD69 and CD71. The study, based on
recruiting twelve patients in each arm and assuming a
standard deviation of 0.78 log 10 copies of HTLV-I DNA
per 100 PBMCs, was powered to detect a difference in
average change from baseline up to 24 weeks (as meas-
ured by area under the curve minus baseline – AUCMB) of
1 log10 copy with 90% power and 5% probability of type
1 error. Therapeutic safety was determined by monitoring
standard haematological and biochemical parameters
according to National Institute of Health, Division of
AIDS criteria[31].
Subjects
Patients were eligible for the study if they had clinical evi-
dence of HAM according to WHO criteria [32], had con-
firmed HTLV-I infection, were aged 18 – 75 years, not
pregnant and willing to use appropriate contraception if
female and sexually active. Patients were excluded if they
had HIV infection, had previous exposure to zidovudine
or lamivudine, had significant haematology, liver or renal
test abnormalities or were unable to give informed con-
sent. Patients were not eligible to enter the study until at
least four weeks after concluding other specific treatment
for HAM e.g. corticosteroids. The study was conducted at
two sites, The HTLV clinic at St. Mary's Hospital, London,
UK and the 3rd Department of Internal Medicine, Univer-
sity of Kagoshima, Kagoshima, Japan. At each site the
local research ethics committee approved the study and
written informed consent was obtained in the local lan-
guage.
Clinical evaluation
Participants underwent a full neurological examination at
weeks 0, 24 and 48 and if new symptoms were reported.
Participants were reviewed monthly with additional visits
at weeks 1, 2, 25 and 26. At each visit a fixed distance walk
was timed and the degree of walking aid documented for
patients able to walk. Disability was graded 1 – 13 as
described by Osame [15]. Pain was quantified using a vis-
ual analogue scale and urinary bladder diary cards record-
ing daytime frequency and nocturia were collected.
Participants were provided with 70 tablets of each com-
pound or matching placebo every four weeks and any
remaining tablets were returned and counted to provide a
measure of adherence.
Laboratory evaluation
Full blood counts, biochemical profile, quantitative
HTLV-I viral DNA and lymphocyte phenotypic assays
were performed at each study visit. The clinical investiga-
tors were blinded to the mean red cell volumes although
these were available for the end of study analysis. Full
blood counts were measured on a Coulter LH750 Ana-
lyzer (Beckman Coulter Inc, Fullerton, CA). The renal,
liver and bone chemistry assays were performed on an
AU2700 Olympus Analyser (Olympus Diagnostica
Gmbh, Hamburg, Germany). HTLV-I viral DNA was
quantified by real-time PCR as previously described. [33].
In addition to the standard T-lymphocyte markers CD3,
CD4, CD8, markers of T-cell activation CD25, CD69 and
proliferation CD71 were assayed described earlier [34].
Statistical analysis
Data from clinical record files were entered into Oracle
databases and checked manually and by computer con-
sistency checks. Analysis text files were created from the
database and imported into STATA for statistical analysis.
Baseline values of laboratory tests were calculated as the
mean of screening and week 0 results. Week 0 data were
taken as baseline for all clinical measurements. Time was
measured from the start of trial treatment and for all
measurements during follow-up data from the closest
date to the target assessment week, within a window of ±Retrovirology 2006, 3:63 http://www.retrovirology.com/content/3/1/63
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2 weeks, were used. HTLV-I proviral load values were con-
verted to copies per 100,000 PBMCs and log10  trans-
formed prior to analysis. Data were analysed as average
change from baseline to a given time point as measured
by AUCMB using the T-test. All analyses were performed
as randomised regardless of changes to study treatment
during follow up. The study was funded by the depart-
ments of the participants. GlaxoSmithKline generously
provided zidovudine and lamivudine for the study and
matching placebos.
Abbreviations
AUCMB Area under the curve minus baseline
CD Cluster of Differentiation
CTL Cytotoxic T- Lymphocyte
DNA Deoxyribonucleic acid
HAM HTLV-I-associated myelopathy
HTLV-I Human T-cell Lymphotropic Virus type I
IFN-γ Interferon-gamma
IL-2 Interleukin – 2
IQR Inter-Quartile Range
MCV Mean cell volume
MDR Multi-drug Resistance
PBMC Peripheral blood mononuclear cell
SD Standard Deviation
SE Standard Error
TNF-α Tumour necrosis factor – alpha
WHO World Health Organisation
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